Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347

Fan,Hongwu; Liu,Guangyao; Zhao,Changfu; Li,Xuefeng; Yang,Xiaoyu

doi:10.3892/ol.2016.5400

Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347

Authors:
- Hongwu Fan
- Guangyao Liu
- Changfu Zhao
- Xuefeng Li
- Xiaoyu Yang
View Affiliations

Affiliations: Department of Orthopedics, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130001, P.R. China, Department of Anesthesiology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130001, P.R. China, Department of Orthopedics, Orthopedics Hospital, The Second Hospital of Jilin University, Changchun, Jilin 130001, P.R. China
Published online on: November 21, 2016 https://doi.org/10.3892/ol.2016.5400
Pages: 396-402

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common primary bone tumor in children and adolescents, typically presenting with a poor prognosis. Octamer-binding transcription factor 4 (Oct4) protein, encoded by the POU class 5 homeobox 1 gene, is important in maintaining self-renewal of pluripotent stem cells, and is closely associated with cancer. However, its role in osteosarcoma remains to be elucidated. The present study observed Oct4 was markedly increased in osteosarcoma cell lines and in human osteosarcoma tissue samples. Following Oct4 downregulation by small interfering RNA (siRNA) in osteosarcoma F5M2 cells, the cells exhibited significant decreases in proliferation and invasion ability, and an increase in cell apoptosis. Notably, downregulation of Oct4 decreased the expression of AK055347, a newly identified long noncoding RNA (lncRNA) in human tissues. The downregulation of AK055347 by siRNA resulted in a significant suppressive effect on proliferative and invasive ability, and promotion of cell apoptosis in osteosarcoma cells. Thus, the current study suggests Oct4 exerts a promoting effect in osteosarcoma, and identifies a novel lncRNA in osteosarcoma progression.

View Figures

View References

1	Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 122:947–956. 2005. View Article : Google Scholar : PubMed/NCBI
2	Bi Y, He Y, Huang J, Su Y, Zhu GH, Wang Y, Qiao M, Zhang BQ, Zhang H, Wang Z, et al: Functional characteristics of reversibly immortalized hepatic progenitor cells derived from mouse embryonic liver. Cell Physiol Biochem. 34:1318–1338. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zeineddine D, Hammoud AA, Mortada M and Boeuf H: The Oct4 protein: More than a magic stemness marker. Am J Stem Cells. 3:74–82. 2014.PubMed/NCBI
4	Chang TS, Wu YC, Chi CC, Su WC, Chang PJ, Lee KF, Tung TH, Wang J, Liu JJ, Tung SY, et al: Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of Oct4/NANOG expression. Clin Cancer Res. 21:201–210. 2015. View Article : Google Scholar : PubMed/NCBI
5	Park SW, Do HJ, Ha WT, Han MH, Park KH, Song H, Kim NH and Kim JH: Transcriptional activation of Oct4 by the ETS transcription factor PEA3 in NCCIT human embryonic carcinoma cells. FEBS Lett. 588:3129–3136. 2014. View Article : Google Scholar : PubMed/NCBI
6	Guzel E, Karatas OF, Duz MB, Solak M, Ittmann M and Ozen M: Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate. 74:1498–1505. 2014. View Article : Google Scholar : PubMed/NCBI
7	Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL and Wu CL: Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res. 68:6281–6291. 2008. View Article : Google Scholar : PubMed/NCBI
8	Li Z, Li X, Li C, Su Y, Fang W, Zhong C, Ji W, Zhang Q and Su C: Transcription factor OCT4 promotes cell cycle progression by regulating CCND1 expression in esophageal carcinoma. Cancer Lett. 354:77–86. 2014. View Article : Google Scholar : PubMed/NCBI
9	Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y, Cao X, Ling EA and Hao A: October4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia. 57:724–733. 2009. View Article : Google Scholar : PubMed/NCBI
10	Borrull A, Ghislin S, Deshayes F, Lauriol J, Alcaide-Loridan C and Middendorp S: Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells. J Cancer Res Clin Oncol. 138:1145–1154. 2012. View Article : Google Scholar : PubMed/NCBI
11	Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, Xie XB, Zeng YX, Shen JN, Kang T and Wang J: Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 311:113–121. 2011. View Article : Google Scholar : PubMed/NCBI
12	Martins-Neves SR, Lopes ÁO, do Carmo A, Paiva AA, Simões PC, Abrunhosa AJ and Gomes CM: Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer. 12:1392012. View Article : Google Scholar : PubMed/NCBI
13	Huang Y, Dai H and Guo QN: TSSC3 overexpression reduces stemness and induces apoptosis of osteosarcoma tumor-initiating cells. Apoptosis. 17:749–761. 2012. View Article : Google Scholar : PubMed/NCBI
14	Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, Wu F and Mo YY: LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res. 41:4976–4987. 2013. View Article : Google Scholar : PubMed/NCBI
15	Isin M and Dalay N: LncRNAs and neoplasia. Clin Chim Acta. 444:280–288. 2015. View Article : Google Scholar : PubMed/NCBI
16	Bauderlique-Le Roy H, Vennin C, Brocqueville G, Spruyt N, Adriaenssens E and Bourette RP: Enrichment of human stem-like prostate cells with s-SHIP promoter activity uncovers a role in stemness for the long noncoding RNA H19. Stem Cells Dev. 24:1252–1262. 2015. View Article : Google Scholar : PubMed/NCBI
17	Shahryari A, Rafiee MR, Fouani Y, Oliae NA, Samaei NM, Shafiee M, Semnani S, Vasei M and Mowla SJ: Two novel splice variants of SOX2OT, SOX2OT-S1 and SOX2OT-S2 are coupregulated with SOX2 and Oct4 in esophageal squamous cell carcinoma. Stem Cells. 32:126–134. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chinese National Institutes of Health, . Ethics examination in biomedicine studies involving the human body. Chinese National Institutes of Health; Beijing, China: 2007
19	Hu J, Fang Y, Cao Y, Qin R and Chen Q: miR-449a regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci. 59:336–345. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang L, Wang J, Wang Y, Fu Q, Lei YH, Nie ZY, Qiu J and Bao TY: Protective effect of exogenous matrix metalloproteinase-9 on chronic renal failure. Exp Ther Med. 7:329–334. 2014.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Lee SH, Koo BS, Kim JM, Huang S, Rho YS, Bae WJ, Kang HJ, Kim YS, Moon JH and Lim YC: Wnt/β-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating October4. J Pathol. 234:99–107. 2014. View Article : Google Scholar : PubMed/NCBI
23	Xiao H, Jiang N, Zhou B, Liu Q and Du C: TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 106:151–159. 2015. View Article : Google Scholar : PubMed/NCBI
24	Vaiphei K, Sinha SK and Kochhar R: Comparative analysis of Oct4 in different histological subtypes of esophageal squamous cell carcinomas in different clinical conditions. Asian Pac J Cancer Prev. 15:3519–3524. 2014. View Article : Google Scholar : PubMed/NCBI
25	Li N, Deng W, Ma J, Wei B, Guo K, Shen W, Zhang Y and Luo S: Prognostic evaluation of nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Med Oncol. 32:4332015. View Article : Google Scholar : PubMed/NCBI
26	Chen ZS, Ling DJ, Zhang YD, Feng JX, Zhang XY and Shi TS: Octamer-binding protein 4 affects the cell biology and phenotypic transition of lung cancer cells involving β-catenin/E-cadherin complex degradation. Mol Med Rep. 11:1851–1858. 2015.PubMed/NCBI
27	Jóźwicki W, Brożyna AA and Siekiera J: Expression of Oct4A: The first step to the next stage of urothelial bladder cancer progression. Int J Mol Sci. 15:16069–16082. 2014. View Article : Google Scholar : PubMed/NCBI
28	Shen L, Qin K, Wang D, Zhang Y, Bai N, Yang S, Luo Y, Xiang R and Tan X: Overexpression of Oct4 suppresses the metastatic potential of breast cancer cells via Rnd1 downregulation. Biochim Biophys Acta. 1842:2087–2095. 2014. View Article : Google Scholar : PubMed/NCBI
29	Li JP, Liu LH, Li J, Chen Y, Jiang XW, Ouyang YR, Liu YQ, Zhong H, Li H and Xiao T: Microarray expression profile of long noncoding RNAs in human osteosarcoma. Biochem Biophys Res Commun. 433:200–206. 2013. View Article : Google Scholar : PubMed/NCBI
30	Dong Y, Liang G, Yuan B, Yang C, Gao R and Zhou X: MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol. 36:1477–1486. 2015. View Article : Google Scholar : PubMed/NCBI
31	Zhang Q, Geng PL, Yin P, Wang XL, Jia JP and Yao J: Down-regulation of long non-coding RNA TUG1 inhibits osteosarcoma cell proliferation and promotes apoptosis. Asian Pac J Cancer Prev. 14:2311–2315. 2013. View Article : Google Scholar : PubMed/NCBI
32	Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, Novokmet A and Malkin D: Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res. 70:160–171. 2010. View Article : Google Scholar : PubMed/NCBI
33	Wang Y, Yao J, Meng H, Yu Z, Wang Z, Yuan X, Chen H and Wang A: A novel long non-coding RNA, hypoxia-inducible factor-2α promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro. Mol Med Rep. 11:2534–2540. 2015.PubMed/NCBI